<DOC>
	<DOCNO>NCT01546038</DOCNO>
	<brief_summary>This study evaluate PF-04449913 ( inhibitor Hedgehog pathway ) Acute Myeloid Leukemia high-risk Myelodysplastic Syndrome combination standard agent use treat disease .</brief_summary>
	<brief_title>A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Patients AML RAEB 2 High Risk MDS newly diagnose accord WHO 2008 Classification previously untreated . Patients AML ( arise antecedent hematologic disease [ AHD ] ) MDS may one prior regimen commercially available agent treatment prior hematologic disease . The patient may prior therapy AML . AML patient include de novo AML , AML evolve MDS AHD AML previous cytotoxic therapy radiation ( secondary AML ) For diagnosis AML , bone marrow blast count 20 % require . For diagnosis highrisk Myelodysplastic Syndrome RAEB 2 patient must 1019 % bone marrow blast Adequate Organ Function ECOG Performance Status 0 , 1 , 2 AML M3 Acute Promyelocytic Leukemia ( APL ) patient ( 9:22 ) cytogenetic translocation . Patients know active uncontrolled central nervous system ( CNS ) leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hedgehog Inhibitor</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>Intensive chemotherapy</keyword>
	<keyword>LDAC</keyword>
</DOC>